Angiotensin blockade improves cardiac and renal complications of type II diabetic rats

Hypertension

Volumn 30, Issue 5, 1997, Pages 1054-1061

  Kim, Shokei ^a   Wanibuchi, Hideki ^a   Hamaguchi, Akinori ^a   Miura, Katsuyuki ^a   Yamanaka, Shinya ^a   Iwao, Hiroshi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Angiotensin converting enzyme inhibition; Diabetes mellitus; Diabetic nephropathy; Insulin resistance; Receptors; Transforming growth factor

Indexed keywords

4' [(2 CYCLOPROPYL 7 METHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL][1,1' BIPHENYL] 2 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CILAZAPRIL; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME INHIBITION; GLOMERULOSCLEROSIS; HEART DISEASE; IMAGE ANALYSIS; INSULIN RESISTANCE; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0030667029     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.30.5.1054     Document Type: Article

References (44)

1. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 1994;23:145-158.
2. Frohlich ED. Left ventricular hypertrophy, cardiac diseases and hypertension: recent experiences. J Am Coll Cardiol. 1989;14: 1587-1594.
3. Sowers J, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. Hypertension. 1995;26(pt 1):869-879.
4. Stern MP. Diabetes and cardiovascular diseases: the "common soil" hypothesis. Diabetes. 1995;44:369-374.
5. Van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation. 1990;82:848-855.
6. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system: an appraisal of present experimental and clinical evidence. Circ Res. 1991;68:905-921.
7. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium, fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
8. Powell J, Clozel J, Muller R, Kuhn H, Hefti F, Hosang M, Baumgartner H. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245: 186-188.
9. Dzau V, Gibbons G, Pratt R. Molecular mechanism of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension. 1991;18(suppl II):II-100-II-105.
10. Ichikawa I, Harris R. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int. 1991;40:583-596.
11. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme therapy on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
12. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925-1930.
13. Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int. 1989;36:526-536.
14. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992;41:1422-1428.
15. Yagi K, Kim S, Wanibuchi H, Yamashita T, Yamamura Y, Iwao H. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima Fatty rats. Hypertension. 1997;29:728-735.
16. Okunishi H, Song K, Oka Y, Kobayashi T, Kawamoto T, Ishihara H, Mori N, Miyazaki M. In vitro pharmacology of a novel non-peptide angiotensin II-receptor antagonist, E4177. Jpn J Pharmacol. 1993;62:239-244.
17. Miyake K, Matsukura M, Yoneda N, Hiroshima O, Mori N, Ishihara H, Musha T, Matsuoka T, Shoji T, Minami N, Hamano S, Saito I. Discovery and development of aryl-fused imidazole-based angiotensin II antagonists. Bioorg Med Chem Lett. 1994;4:213-218.
18. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, Iwao H. Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int. 1994;46:1346-1358.
19. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Iwao H. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension. 1995;25:1252-1259.
20. Qian SW, Kondaiah P, Roberts AB, Sporn MB. cDNA cloning by PCR of rat transforming growth factor β-1. Nucleic Acids Res. 1990;18:3059.
21. Fort P, Marty L, Piechaczyk M, el-Sabrouty S, Dani C, Jeanteur P, Blanchard JM. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res. 1985;13:1431-1442.
22. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension. 1995;26(pt 1):957-962.
23. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int. 1984; 26:137-143.
24. Hamaguchi A, Kim S, Wanibuchi H, Iwao H. Angiotensin II and calcium blockers prevent glomerular phenotypic changes in remnant kidney model. J Am Soc Nephrol. 1996;7:687-693.
25. Weibel ER. Stereological Methods: Practical Methods for Biological Morphometry. London, UK: Academic Press Inc; 1979:51-57.
26. Everett A, Tufro-McReddie A, Fisher A, Gomez R. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-β1 expression. Hypertension. 1995;23:587-592.
27. Brilla CG, Maisch B, Weber KT. Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. Clin Invest. 1993;71:S35-S41.
28. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H. Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats. Br J Pharmacol. 1996;118:549-556.
29. Ohta K, Kim S, Iwao H. Role of angiotensin-converting enzyme, adrenergic receptors and blood pressure in cardiac gene expression of spontaneously hypertensive rats during the development. Hypertension. 1996;28:627-634.
30. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodeling in myocardial-infarcted rats. J Mol Cell Cardiol. 1993;25:1369-1380.
31. Latini R, Maggioni A, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation. 1995;92:3132-3137.
32. Yoshiyama M, Kim S, Yamagishi H, Omura T, Tani T, Yanagi S, Toda I, Teragaki M, Akioka K, Takeuchi K, Takeda T. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J. 1994;128:1-6.
33. Sechi LA, Griffin CA, Schambelan M. The cardiac renin-angiotensin system in STZ-induced diabetes. Diabetes. 1994;43:1180-1184.
34. Border WA, Ruoslahti E. Transforming growth factor-β1 in disease: the dark side of tissue repair. J Clin Invest. 1992;90:1-7.
35. Eghbali M, Tomek R, Sukhatme VP, Woods C, Bhambi B. Differential effects of transforming growth factor-β1 and phorbol myristate acetate on cardiac fibroblasts. Circ Res. 1991;69:483-490.
36. Kim S, Kawamura M, Wanibuchi H, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Iwao H. Angiotensin II type I receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery. Circulation. 1995;92:88-95.
37. Hajinazarian M, Cosio FG, Nahman NS, Mahan JD. Angiotensin-converting enzyme inhibition partially prevents diabetic organomegaly. Am J Kidney Dis. 1994;23:105-117.
38. Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, Bertani T, Remuzzi G. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol. 1993;4:40-49.
39. Blaufarb IS, Sonnenblick EH. The renin-angiotensin system in left ventricular remodeling. Am J Cardiol. 1996;77:8C-16C.
40. Komers R, Cooper M. Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins. Am J Physiol. 1995;268:F588-F594.
41. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt R, Dzau V. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A. 1995;92:10663-10667.
42. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-657.
43. Sechi L, Griffin C, Schambelan M. Tissue specific regulation of angiotensin II receptors and ATI mRNA in diabetes mellitus. J Am Soc Nephrol. 1992;3:A765. Abstract.
44. Chen S, Noguchi Y, Izumida T, Tatebe J, Katayama S. A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. J Hypertens. 1996;14:1325-1330.